Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $35

Baird analyst Brian Skorney maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $52 to $35.

byBenzinga Newsdesk

October 3, 2022

1 minute read

Baird analyst Brian Skorney maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $52 to $35.

NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights

By Vandana Singh

Today, 4:38 AM

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has

NRXP

Telsey Advisory Group Maintains Outperform on Under Armour, Lowers Price Target to $12

By Benzinga Newsdesk

Today, 4:38 AM

Telsey Advisory Group analyst Cristina Fernandez maintains Under Armour (NYSE:UAA) with a Outperform and lowers the price target from $17 to $12.

Horace Mann Raises 2021 EPS Guidance From $3.00-$3.20 To $3.50-$3.70

By Benzinga Newsdesk

Today, 4:38 AM

Horace Mann Educators Corporation (NYSE:HMN) today announced it is raising guidance for its 2021 EPS by more than 15% to $3.50 to $3.70 from $3.00 to $3.20, with

HMN

Morgan Stanley Maintains Overweight on Paramount Group, Lowers Price Target to $10.5

By Benzinga Newsdesk

Today, 4:38 AM

Morgan Stanley analyst Vikram Malhotra maintains Paramount Group (NYSE:PGRE) with a Overweight and lowers the price target from $11 to $10.5.

PGRE

Baird Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $35

Related Posts

NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights

Telsey Advisory Group Maintains Outperform on Under Armour, Lowers Price Target to $12

Horace Mann Raises 2021 EPS Guidance From $3.00-$3.20 To $3.50-$3.70

Morgan Stanley Maintains Overweight on Paramount Group, Lowers Price Target to $10.5